-

Cagent Vascular Announces Launch of New Product Serranator SL-PRO for CLTI and Pedal Disease

WAYNE, Penn.--(BUSINESS WIRE)--Cagent Vascular, Inc., the exclusive developer of serration technology for vessel dilation in endovascular interventions, today announced the launch of its newest product, Serranator SL-PRO™ PTA Serration Balloon Catheter.

Serranator SL-PRO™ is purpose-built for pedal intervention as well as challenging-to-cross tibial disease. Serranator SL-PRO™ utilizes Cagent’s proven Serration Technology on a redesigned platform offering improved deliverability and trackability1, while offering Serranator’s proven 1,000 times increase in point force versus plain balloon. Its innovative mechanism of action allows for predictable and controlled lumen gain with minimal dissection.

Dr. Michael Lichtenberg (Chief Medical Officer and Director of the Angiology Department and Vascular Center at the Arnsberg Clinic in Arnsberg, Germany) said, “As an experienced Serranator operator, my team has grown accustomed to the benefits of Serration including great lumen gain, low complication rate, and low 6% BTK vessel recoil vs. 55% measured recoil with Plain Balloon2.” Dr. Lichtenberg continued, “We also appreciate Serranator’s ability to safely and effectively treat complex disease, even down into the pedal arteries. With SL-PRO, we’re eager to experience the advantages of Serranation in this new, more deliverable platform.”

Cagent Vascular Chairman and CEO Brian Walsh added, "We are committed to consistently developing and advancing solutions for physicians treating PAD patients, and winning the fight against this debilitating disease. With over 20,000 Serranation procedures now completed and a growing library of clinical data, Serranator has proven itself to be a valuable tool in this fight. The Serranator SL-PRO™ is a purpose-built tool for pedal intervention, and with it, the Serranator product family can now treat from hip to toe.”

The Serranator® and Serranator SL-PRO™ PTA Serration Balloon Catheters are FDA-cleared, novel balloons using proprietary stainless steel micro-serration technology, designed to create linear, interrupted scoring along the endoluminal surface. With 1,000x more point force compared with plain-old balloon angioplasty, serration occurs during slow-and-low balloon inflation and is designed to aid arterial expansion, effectively achieving luminal gain in all lesion morphologies.

For ordering information, please visit https://cagentvascular.com/ or contact info@cagentvascular.com

1 TD-0761 Serranator SL-PRO Independent Product Performance Report.

2 Fereydooni A, Chandra V, Schneider PA, Giasolli R, Lichtenberg M, Stahlhoff S. Serration Angioplasty Is Associated With Less Recoil in Infrapopliteal Arteries Compared With Plain Balloon Angioplasty. J Endovasc Ther. 2023 Dec 7:15266028231215284.

Contacts

Cagent Communications and Media Contact:
Lauren Pfeiffer
+1 610-688-2006
LPfeiffer@cagentvascular.com

Cagent Vascular


Release Versions

Contacts

Cagent Communications and Media Contact:
Lauren Pfeiffer
+1 610-688-2006
LPfeiffer@cagentvascular.com

Social Media Profiles
More News From Cagent Vascular

Cagent Vascular Initiates Patient Enrollment in the Serranator® vs. POBA OCT Study at Columbia University Medical Center

WAYNE, Pa.--(BUSINESS WIRE)--Cagent Vascular, Inc., the exclusive developer of serration technology for vessel dilation in endovascular interventions, announced its 1st patient enrollment of the Serranator vs. POBA OCT Study. This prospective, randomized (2:1 treatment to control) dual-center study will enroll up to 60 subjects. The study will utilize intravascular optical coherence tomography (OCT) imaging to demonstrate the mechanism of action (MOA) of the Serranator and compare the Serration...

Cagent Vascular and 3comma Medical Announce Strategic Partnership to Expand International Distribution of Serranator Product Family in EU and MENA Regions

WAYNE, Pa.--(BUSINESS WIRE)--Cagent Vascular, Inc., the exclusive developer of serration technology for vessel dilation in endovascular interventions, today announced its strategic partnership with 3comma Medical GmbH, a commercial services firm that specializes in bringing innovative medical device products to international markets. Under this collaboration, 3comma will serve as the exclusive international (OUS) distributor in EU and MENA regions for Cagent Vascular, leveraging its extensive n...

Cagent Vascular Appoints Paul Wilson as Chief Commercial Officer to Drive Growth and Market Expansion

WAYNE, Penn.--(BUSINESS WIRE)--Cagent Vascular, Inc., the exclusive developer of serration technology for vessel dilation in endovascular interventions, today announced the appointment of Paul Wilson as Chief Commercial Officer (CCO). In this role, Mr. Wilson will lead the company’s commercial strategy, overseeing sales, marketing, clinical programming, and business development initiatives. His leadership will help expand awareness, accelerate growth, and strengthen market positioning of Cagent...
Back to Newsroom